Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROCCO T SERRAO

Allopathic & Osteopathic Physicians Dermatology

NPI
1124274477
CMS profile
1135782
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$276,170.15

399 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 8 of 8; records 351–399 of 399 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROCCO T SERRAO

NPI 1124274477 · CMS profile ID 1135782

Allopathic & Osteopathic Physicians / Dermatology

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 8; records 351–399 of 399 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124274477?year=2023&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROCCO T SERRAO, NPI 1124274477, CMS profile ID 1135782. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–399 of 399 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124274477?year=2023&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROCCO T SERRAO, NPI 1124274477, CMS profile ID 1135782. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–399 of 399 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124274477?year=2023&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROCCO T SERRAO, NPI 1124274477, CMS profile ID 1135782, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–399 of 399 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124274477?year=2023&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

399 matching records · $276,170.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 399 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–399 of 399.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $18.9702/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427640 CMS
Regeneron Healthcare Solutions, Inc. $21.6902/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427645 CMS
Regeneron Healthcare Solutions, Inc. $101.7302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427651 CMS
Regeneron Healthcare Solutions, Inc. $3,450.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427635 CMS
Dermavant Sciences, Inc. $1,200.0002/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991250087 CMS
Lilly USA, LLC $8.0902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032164907 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996839219 CMS
Lilly USA, LLC $3,500.0002/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032289053 CMS
Regeneron Healthcare Solutions, Inc. $25.5802/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427629 CMS
AbbVie Inc. $2,625.0002/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911369 CMS
Dermavant Sciences, Inc. $16.1802/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991250083 CMS
Regeneron Healthcare Solutions, Inc. $114.3302/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427623 CMS
AbbVie Inc. $9.4202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911363 CMS
Lilly USA, LLC $438.5402/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032035315 CMS
Lilly USA, LLC $24.9202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032035321 CMS
Lilly USA, LLC $59.8502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032130835 CMS
Lilly USA, LLC $139.6602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032130839 CMS
Lilly USA, LLC $50.0002/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032155271 CMS
Lilly USA, LLC $44.8902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032164885 CMS
Lilly USA, LLC $160.8002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032164891 CMS
Lilly USA, LLC $49.8902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032251735 CMS
Lilly USA, LLC $160.8002/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032376367 CMS
AbbVie Inc. $2,625.0001/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911351 CMS
AbbVie Inc. $70.0101/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911357 CMS
AbbVie Inc. $3,675.0001/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911337 CMS
AbbVie Inc. $12.8001/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911346 CMS
AbbVie Inc. $1,050.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911333 CMS
AbbVie Inc. $4.9601/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911321 CMS
AbbVie Inc. $113.6801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911327 CMS
Arcutis Biotherapeutics, Inc. $4.8201/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044842607 CMS
Arcutis Biotherapeutics, Inc. $15.0601/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044842619 CMS
AbbVie Inc. $1,272.4601/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911307 CMS
AbbVie Inc. $57.4201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911313 CMS
E.R. Squibb & Sons, L.L.C. $3,575.0001/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016193245 CMS
E.R. Squibb & Sons, L.L.C. $7.4901/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016193269 CMS
Regeneron Healthcare Solutions, Inc. $746.4101/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999427617 CMS
Lilly USA, LLC $2,000.0001/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032251741 CMS
Lilly USA, LLC $750.0001/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032331003 CMS
Dermavant Sciences, Inc. $124.2201/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991250079 CMS
Dermavant Sciences, Inc. $18.7801/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991250075 CMS
AbbVie Inc. $5.4701/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911299 CMS
PFIZER INC. $4.6101/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050623493 CMS
Incyte Corporation $13.4901/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044805085 CMS
LEO Pharma Inc. $28.3301/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053526581 CMS
AbbVie Inc. $11.2601/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911281 CMS
AbbVie Inc. $1.3001/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911289 CMS
AbbVie Inc. $2.5701/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998911295 CMS
Arcutis Biotherapeutics, Inc. $4.4401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044842631 CMS
Novartis Pharmaceuticals Corporation $24.5301/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993403173 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $266,545.50 323
PY2020 $121,706.72 141
PY2021 $81,779.41 151
PY2022 $211,314.88 283
PY2023 $276,170.15 399
PY2024 $335,129.85 500
PY2025 $411,440.28 458

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $324,991.41 40
PY2024 Recipient $5,256.58 2
PY2024 Principal investigator $259,075.02 207
PY2023 Principal investigator $122,877.34 148
PY2022 Recipient $23.00 1
PY2022 Principal investigator $138,191.54 46
PY2021 Principal investigator $113,742.91 29
PY2020 Recipient $721.95 2
PY2020 Principal investigator $111,871.69 19
PY2019 Recipient $7,643.80 3
PY2019 Principal investigator $218,861.36 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF GREATER COLUMBUS
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533699
Principal investigator 1 Sun Pharmaceutical Industries Inc. $18,000.00 12/11/2025 Non-covered Recipient Entity
Probity Medical Research Corp.
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797070
Principal investigator 1 ABBVIE INC. $8,051.25 12/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529034
Principal investigator 1 ABBVIE INC. $1,607.25 12/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202529042
Principal investigator 1 ABBVIE INC. $12,060.88 11/24/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202525204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 11/18/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184261787
Principal investigator 1 ABBVIE INC. $11,977.55 11/05/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522425
Principal investigator 1 ABBVIE INC. $17,160.60 11/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520589
Principal investigator 1 ABBVIE INC. $30,118.50 11/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520701
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Dermatologists Of Southwest Ohio, Inc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251532
Principal investigator 1 ABBVIE INC. $14,456.97 10/09/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515411
Principal investigator 1 ABBVIE INC. $14,688.75 09/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509344
Principal investigator 1 ABBVIE INC. $12,064.00 08/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503401
Principal investigator 1 ABBVIE INC. $4,809.60 07/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202496779
Principal investigator 1 ABBVIE INC. $13,103.50 07/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496781
Principal investigator 1 ABBVIE INC. $9,477.00 07/02/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184208965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184208969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/18/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209003
Principal investigator 1 ABBVIE INC. $2,032.50 06/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489485
Principal investigator 1 ABBVIE INC. $3,342.75 06/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489487
Principal investigator 1 ABBVIE INC. $10,991.70 06/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 05/21/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWESTERN OHIO LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184197481
Principal investigator 1 ABBVIE INC. $19,101.65 05/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483653
Principal investigator 1 ABBVIE INC. $10,049.85 05/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483655
Principal investigator 1 ABBVIE INC. $13,219.20 05/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482009
Principal investigator 1 ABBVIE INC. $5,562.00 04/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470512
Principal investigator 1 ABBVIE INC. $3,687.00 04/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202470515
Principal investigator 1 ABBVIE INC. $10,330.55 04/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470520
Principal investigator 1 ABBVIE INC. $16,651.35 03/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460478
Principal investigator 1 ABBVIE INC. $3,761.25 03/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460646
Principal investigator 1 ABBVIE INC. $4,772.25 03/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457601
Principal investigator 1 ABBVIE INC. $12,251.25 02/12/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202450622
Principal investigator 1 ABBVIE INC. $8,611.35 02/12/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202450695
Principal investigator 1 ABBVIE INC. $21,839.45 02/12/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202450698
Principal investigator 1 Eli Lilly and Company $2,770.77 02/05/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880463
Principal investigator 1 ABBVIE INC. $3,660.00 01/02/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202434853